Zum Hauptinhalt springen

Icariin attenuates lipopolysaccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-kappaB and JNK/p38 MAPK pathways.

Zeng, KW ; Fu, H ; et al.
In: International immunopharmacology, Jg. 10 (2010-06-01), Heft 6, S. 668
Online academicJournal

Titel:
Icariin attenuates lipopolysaccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-kappaB and JNK/p38 MAPK pathways.
Autor/in / Beteiligte Person: Zeng, KW ; Fu, H ; Liu, GX ; Wang, XM
Link:
Zeitschrift: International immunopharmacology, Jg. 10 (2010-06-01), Heft 6, S. 668
Veröffentlichung: Amsterdam ; New York : Elsevier Science, c2001-, 2010
Medientyp: academicJournal
ISSN: 1878-1705 (electronic)
DOI: 10.1016/j.intimp.2010.03.010
Schlagwort:
  • Animals
  • Cell Death drug effects
  • Cerebral Cortex drug effects
  • Cerebral Cortex pathology
  • Cyclooxygenase 2 analysis
  • Cytokines analysis
  • Cytokines metabolism
  • Dinoprostone analysis
  • Dinoprostone metabolism
  • Encephalitis drug therapy
  • I-kappa B Kinase metabolism
  • JNK Mitogen-Activated Protein Kinases metabolism
  • Lipopolysaccharides
  • MAP Kinase Kinase Kinases metabolism
  • Microglia enzymology
  • NF-kappa B metabolism
  • Neurons enzymology
  • Nitric Oxide analysis
  • Nitric Oxide metabolism
  • Nitric Oxide Synthase Type II analysis
  • Phosphorylation
  • Rats
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species analysis
  • Reactive Oxygen Species metabolism
  • p38 Mitogen-Activated Protein Kinases metabolism
  • Flavonoids pharmacology
  • I-kappa B Kinase antagonists & inhibitors
  • JNK Mitogen-Activated Protein Kinases antagonists & inhibitors
  • MAP Kinase Kinase Kinases antagonists & inhibitors
  • Microglia drug effects
  • NF-kappa B antagonists & inhibitors
  • Neurons drug effects
  • Neuroprotective Agents pharmacology
  • p38 Mitogen-Activated Protein Kinases antagonists & inhibitors
Sonstiges:
  • Nachgewiesen in: MEDLINE
  • Sprachen: English
  • Publication Type: Journal Article; Research Support, Non-U.S. Gov't
  • Language: English
  • [Int Immunopharmacol] 2010 Jun; Vol. 10 (6), pp. 668-78. <i>Date of Electronic Publication: </i>2010 Mar 25.
  • MeSH Terms: Flavonoids / *pharmacology ; I-kappa B Kinase / *antagonists & inhibitors ; JNK Mitogen-Activated Protein Kinases / *antagonists & inhibitors ; MAP Kinase Kinase Kinases / *antagonists & inhibitors ; Microglia / *drug effects ; NF-kappa B / *antagonists & inhibitors ; Neurons / *drug effects ; Neuroprotective Agents / *pharmacology ; p38 Mitogen-Activated Protein Kinases / *antagonists & inhibitors ; Animals ; Cell Death / drug effects ; Cerebral Cortex / drug effects ; Cerebral Cortex / pathology ; Cyclooxygenase 2 / analysis ; Cytokines / analysis ; Cytokines / metabolism ; Dinoprostone / analysis ; Dinoprostone / metabolism ; Encephalitis / drug therapy ; I-kappa B Kinase / metabolism ; JNK Mitogen-Activated Protein Kinases / metabolism ; Lipopolysaccharides ; MAP Kinase Kinase Kinases / metabolism ; Microglia / enzymology ; NF-kappa B / metabolism ; Neurons / enzymology ; Nitric Oxide / analysis ; Nitric Oxide / metabolism ; Nitric Oxide Synthase Type II / analysis ; Phosphorylation ; Rats ; Rats, Sprague-Dawley ; Reactive Oxygen Species / analysis ; Reactive Oxygen Species / metabolism ; p38 Mitogen-Activated Protein Kinases / metabolism
  • Substance Nomenclature: 0 (Cytokines) ; 0 (Flavonoids) ; 0 (Lipopolysaccharides) ; 0 (NF-kappa B) ; 0 (Neuroprotective Agents) ; 0 (Reactive Oxygen Species) ; 31C4KY9ESH (Nitric Oxide) ; EC 1.14.13.39 (Nitric Oxide Synthase Type II) ; EC 1.14.99.1 (Cyclooxygenase 2) ; EC 2.7.11.10 (I-kappa B Kinase) ; EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases) ; EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases) ; EC 2.7.11.25 (MAP Kinase Kinase Kinases) ; EC 2.7.11.25 (MAP kinase kinase kinase 7) ; K7Q1JQR04M (Dinoprostone) ; VNM47R2QSQ (icariin)
  • Entry Date(s): Date Created: 20100330 Date Completed: 20100903 Latest Revision: 20220408
  • Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -